Lipid microspheres as drug carriers: A pharmaceutical point of view

Advanced Drug Delivery Reviews

Volumn 20, Issue 2-3, 1996, Pages 117-130

  Yamaguchi, Tetsuo ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

DLVO theory; Drug delivery; Emulsion; Lipid microsphere; Lipo PGE1; Prostaglandin E1; Retentivity; Stability; Targeting

Indexed keywords

COALESCENCE; DRUG INFUSION; DRUG PRODUCTS; EMULSIONS; EVALUATION; FLOCCULATION; INTERFACES (MATERIALS); LIPIDS; PHARMACODYNAMICS; PROTEINS; STABILITY;

CLINICAL EFFICACY; DLVO THEORY; DRUG CARRIERS; DRUG DELIVERY; LIPID MICROSPHERES; PHYSICOCHEMICAL PROPERTIES; PROSTAGLANDIN E; RETENTIVITY; TARGETING; TRANSFUSION;

DRUG THERAPY;

ALPHA CYCLODEXTRIN; GLYCEROL; LIPID; LIPOPROSTAGLANDIN E1; MICROSPHERE; OIL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PROSTAGLANDIN E1; SOYBEAN OIL; WATER;

DRUG ADMINISTRATION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; FLOCCULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PARTICLE SIZE; PH; PHARMACEUTICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TEMPERATURE; THEORY; TRANSFUSION;

EID: 0030602835     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00115-N     Document Type: Review

References (95)

1. 1 on microvascular haemodynamics in progressive systemic sclerosis. Br. Med. J. 285, 1688.
2. [2] Gross, R., Greenberg, M., Strain, J. and Mueller, H. (1985) Intracoronary prostacyclin in evolving acute myocardial infarction. Am. J. Cardiol. 55, 1625-1626.
3. 1 in infants with critical congenital heart disease. Circulation 64, 893-898.
4. [4] Fendler, J.H. and Romero, A. (1977) Liposomes as drug carriers. Life Sci. 20, 1109-1120.
5. [5] Shaw, I.H., Knight, C.G., Thomas, D.P.P., Phillips, N.C. and Dingle, J.T. (1979) Liposome-incorporated corticosteroids: I. The interaction of liposomal cortisol palmitate with inflammatory synovial membrane. Br. J. Exp. Pathol. 60, 142-150.
6. [6] Yamauchi, H. and Kikuchi, H. (1987) Properties and preparation of liposomes. Fragrance J. 87, 68-76.
7. [7] Katre, N.V., Knauf, M.J. and Laird, W.J. (1987) Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. U.S.A. 84, 1487-1491.
8. [8] Oku, N. and Doi, K. (1994) Application of RES-avoiding liposomes encapsulated adriamycin for cancer therapy. Drug Delivery System 9, 89-95.
9. [9] Tuzar, Z. and Kratochvil, P. (1976) Block and graft copolymer micelles in solution. Adv. Colloid Interface Sci. 6, 201-232.
10. [10] Yokoyama, M., Miyauchi, M., Yamada, N., Okano, T., Sakurai, Y., Kataoka, K. and Inoue, S. (1990) Polymeric micelle as novel carrier: adriamycin-conjugated poly(ethyleneglycol)-poly(aspartic acid) block copolymer. J. Controlled Release 11, 269-278.
11. [11] Nakanishi, M., Uchida, T., Sugawa, H., Ishiura, M. and Okada, Y. (1985) Efficient introduction of contents of liposomes into cells using HVJ (sendai virus). Exp. Cell Res. 159, 399-409.
12. [12] Koga, Y., Swanson, V.L. and Hayes, D.M. (1975) Hepatic "Intravenous fat pigment" in infants and children receiving lipid emulsion. Pediatric Surgery 10, 641-648.
13. [13] Fischer, G.W., Hunter, K.W., Wilson, S.R. and Mease, A.D. (1980) Diminished bacterial defences with intralipid. Lancet 2, 819-820.
14. [14] Yanagawa, A. (1982) Application of lipid particles as a novel carrier for various drugs. Jpn. J. Inflamm. 2, 251-257.
15. [15] Majima, Y., Tashiro, A., Yamamori, H. and Okui, K. (1986) Fat emulsion as an energy source in peripheral parenteral nutrition. Pharm. Med. 4, 109-115.
16. [16] Hogskilde, S., Nielsen, J.W., Carl, P. and Sorensen, M.B. (1987) Pregnenolone emulsion. A new steroid preparation for intravenous anaesthesia an experimental study in mice. Anesthesia 42, 586-590.
17. [17] Kimura, N. (1987) Fat emulsion for intravenous infusion. Infantile Surgery 19, 995-1005.
18. [18] Sayeed, F.A., Tripp, M.G., Sukumaran, K.G., Mikrut, B.A., Stelmach, H.A. and Raihle, J.A. (1987) Stability of total nutrient admixtures using various intravenous fat emulsions. Am. J. Hosp. Pharm. 44, 2271-2280.
19. [19] Jeppsson, R. (1972) Effects of barbituric acids using an emulsion form intravenously. Acta. Pharma. Succ. 9, 81-90.
20. [20] Jeppsson, R. and Ljungberg, S. (1973) Intraarterial administration of emulsion formulations containing cyclandelate and nitroglycerin. Acta. Pharma. Succ. 10, 129-140.
21. [21] Mizushima, Y. (1985) Lipid microspheres as novel drug carriers. Drugs Exp. Clin. Res. XI, 595-600.
22. [22] Collins-Gold, L.C., Lyonsa, R.T. and Bartholow, L.C. (1990) Parenteral emulsions for drug delivery. Adv. Drug Delivery Rev. 5, 189-208.
23. [23] Skeie, B., Askanazi, J., Rothkopf, M., Rosenbaum, S., Kvetan, V. and Thomashow, B. (1988) Intravenous fat emulsions and lung function, A review. Crit. Care Med. 16, 183-192.
24. [24] Illum, L., West, P., Washington, C. and Davis, S.S. (1989) The effect of stabilizing on the organ distribution of lipid emulsions. Int. J. Pharm. 54, 41-49.
25. [25] Mizushima, Y. (1988) Application of lipid microspheres for targeting therapy. J. Bioactive Compatible Polymers 3, 148-156.
26. [26] Mizushima, Y. (1991) Lipo-prostaglandin preparations. Prostagl. Leukotr. Essent. Fatty Acids 42, 1-6.
27. [27] Mizushima, Y. and Hoshi, K. (1993) Review: recent advances in lipid microsphere technology for targeting prostaglandin delivery. J. Drug Targeting 1, 93-100.
28. 99mTc labeled lipid microspheres would be useful for an imaging study of various diseases. Jpn. J. Inflamm. 7, 551-557.
29. 1 to vascular lesions. Prostagl. Leukotr. Essent. Fatty Acids 41, 269-272.
30. 1. J. Pharm. Pharmcol. 35, 397.
31. [31] Mizushima, Y., Hamano, T. and Yokoyama, K. (1982) Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann. Rheum. Dis. 41, 263-267.
32. [32] Mizushima, Y., Wada, Y., Etoh, Y. and Watanabe, K. (1983) Anti-inflammatory effects of indomethacin ester incorporated in a lipid microsphere. J. Pharm. Pharmacol. 35, 398-399.
33. [33] Yokoyama, K., Okamoto, H., Watanabe, M., Suyama, T. and Mizushima, Y. (1985) Development of a corticosteroid incorporated in lipid microspheres (liposteroido). Drugs Exp. Clin. Res. 11, 611-620.
34. [34] Shoji, Y., Mizushima, Y., Yanagawa, A., Shiba, T., Takei, H., Fujii, M. and Amino, M. (1986) Enhancement of anti-inflammatory effects of biphenylylacetic acid by its incorporation into lipid microspheres. J. Pharm. Pharmacol. 38, 118-122.
35. 1). Drugs Exptl. Clin. Res. XI, 627.
36. 1 incorporated in lipid microspheres on thrombus formation and thrombus disaggregation and its potential to target to the site of vascular lesions. Arzneim.-Forsch./Drug Res. 36, 1206-1209.
37. [37] Mizushima, Y., Igarashi, R., Hoshi, K., Sim, A.K., Cleland, M.E., Hayashi, H. and Goto, J. (1987) Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspheres. Prostaglandins 33, 161-168.
38. [38] Elliott, R.B., Starling, M.B. and Neutze, J.M. (1975) Medical manipulation of the ducts arteriosus. Lancet 1, 140-141.
39. 1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders. J. Rheumatol. 14, 97-101.
40. 1) in the treatment of systemic sclerosis (SS). Ann. Rheum. Dis. 39, 194-195.
41. 1 and the application of them to lipid microsphere (LM) preparations. Ensho 8, 243.
42. [42] Hallberg, D. (1965) Elimination of exogenous lipids from the blood stream. Acta Physiol. Scand. 65, 254.
43. [43] Krauss, R.M., Levy, R.I. and Fredrickson, D.S. (1974) Selective measurement of two lipase activities in post-heparin plasma from normal subjects and patients with hyperlipoproteinemia. J. Clin. Invest. 54, 1107-1124.
44. [44] Yoshioka, T., Noma, J., Eguchi, K. and Sekiba, K. (1981) Lipid metabolism in pregnancy, metabolism of intravenously injected fat emulsion. Acta Obst. Gynaec. Jpn. 33, 34-40.
45. [45] Iriyama, K., Mori, K., Teranishi, T., Nishiwaki, H., Kusaka, N. and Suzuki, H. (1985) Metabolism of intravenously administered lipid emulsion under intraperitoneal sepsis. Saishin Igaku 40, 2137-2145.
46. [46] Okuno, M., Nagayama, M., Ikehara, T., Takai, T., Sakamoto, K., Lee, J.T., Kamino, K. and Umeyama, K. (1986) Serum fatty acid concentrations in patients on postoperative parenteral nutrition with and without fat. Jpn. J. Surg. 16, 118-125.
47. 1 on dog forelimb skin and muscle blood flow. Am. J. Physiol. 220, 392-396.
48. 1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins 46, 453-468.
49. [49] Dyck, P.J., Hansen, S. and Karnes, J. (1985) Capillary number and percentage closed in human diabetic surreal nerve. Proc. Natl. Acad. Sci. U.S.A. 82, 2513-2517.
50. [50] Johnson, P.C., Doll, S.C. and Cromey, D.W. (1986) Pathogenesis of diabetic neuropathy. Ann. Neurol. 19, 450.
51. [51] Low, P.A., Schmelzer, J.D., Ward, J.J. and Yao, J.K. (1986) Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am. J. Physiol. 250, E94-E99.
52. [52] Sima, A.A.F., Nathaniel, V., Bril, V., McEwen, T.A.J. and Greene, D.A. (1988) Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes and demonstration of axo-glial disjunction in human diabetic neuropathy. J. Clin. Invest. 81, 349.
53. 1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J. Pharm. Pharmacol. 35, 666-667.
54. 1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Drugs Exp. Clin. Res. 12, 681-685.
55. [55] Ohtsu, A., Fujii, K. and Kurozumi, S. (1988) Induction of angiogenic response by chemically stable prostacyclin analogs. Prostagl. Leukotr. Essent. Fatty Acids 33, 35-39.
56. 2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction. Prostaglandins 40, 155-164.
57. [57] Minagawa, T., Kohno, Y., Suwa, T. and Tsuji, A. (1994) Evaluation of entrapping efficiency and drug-release profile of an O/W emulsion formulation using a new method, polydimethylsiloxane-coated glass beads assay. Pharm. Res. 11, 503-507.
58. [58] Shibasaki, M., Trisawa, Y. and Ikegami, S. (1983) Synthesis of 9(O)-methano-6(9alfa)-PGI1: the highly potent carbon analog of prostacyclin. Tetrahedron Lett. 24, 3493-3496.
59. [59] Gryglewski, R.J. (1985) Effect of prostacyclin in atherosclerotic vascular disease. Adv. Prostagl. Tromboxane Leukotr. Res. 15, 539-542.
60. 1 prodrug for targeting therapy. J. Controlled Rel. 20, 37-46.
61. 2 incorporated in lipid microspheres, for targeted delivery. J. Controlled Rel. 28, 243-249.
62. 1 J. Med. 25, 371-395.
63. 1). Jpn. Pharmacol. Ther. 23, 565-577.
64. 1 in oil phase of lipid microsphere preparations. Clin. Rep. 26, 1647-1652.
65. 1 in lipid emulsion in relation to release rate from lipid particles. Chem. Pharm. Bull. 42, 646-650.
66. [66] Uekama, K., Hirayama, F., Tanaka, H. and Takematsu, K. (1978) Partition behavior and ion pair formation of some prostaglandins. Chem. Pharm. Bull. 26, 3779-3784.
67. 1 in a lipid emulsion by ultrafiltration. Pharm. Res. 5, 482-487.
68. 1 in a lipid emulsion. Pharm. Res. 6, 210-215.
69. 1 in lipid emulsion. Biochim. Biophys. Acta 1256, 381-386.
70. 1 in lipid particles in the case of drip infusion. Clin. Rep. 29, 1631-1640.
71. [71] Marra, J. (1986) Direct measurement of the interaction between phosphatidylglycerol bilayers in aqueous electrolyte solutions. Biophys. J. 50, 815-825.
72. [72] Makino, K., Yamada, T., Kimura, K., Oka, T., Ohshima, H. and Kondo, T. (1991) Temperature and ionic strength-induced conformational changes in the lipid head group region of liposomes as suggested by zeta potential data. Biophys. Chem. 41, 175-183.
73. [73] Ishii, F., Takamura, A., Noro, S., Tanifuji, M. and Ibuki, F. (1984) Effect of some phospholipid compositions on emulsion stability. YAKUZAIGAKU 44, 215-221.
74. [74] Mervat, B., Dharma, R.K. and Trevor, G.R. (1986) Effects of lipid composition on the association of plasma proteins with lipid emulsions. J. Colloid Interface Sci. 113, 414-420.
75. [75] Ishii, F., Sasaki, I. and Ogata, H. (1989) Effect of phospholipid emulsifiers on physicochemical properties of intravenous fat emulsions and/or drug carrier emulsions. J. Pharm. Pharmacol. 42, 513-515.
76. [76] Ishii, F., Nagasaka, Y. and Ogata, H. (1989) Interaction between erythrocytes from various animals and emulsions stabilized with various lecithins. J. Pharm. Sci. 78, 303-306.
77. [77] Ueda, K. and Matsumoto, S. (1991) Effect of proteins on the zeta potential of dispersed vesicular globules in W/O/W emulsions. Bull. Chem. Soc. Jpn. 64, 3163-3165.
78. [78] Yamaguchi, T., Nishizaki, K., Itai, S., Nemoto, M. and Ohshima, H. (1995) Adsorption of divalent cations onto the membrane surface of lipid emulsion. Colloids and Surfaces. B: Biointerfaces 5, 49-55.
79. [79] Higuchi, W.I. and Misra, J. (1962) Physical degradation of emulsions via the molecular diffusion route and the possible prevention thereof. J. Pharm. Sci. 51, 459-466.
80. [80] Takamura, A., Ishii, F., Noro, S. and Koishi, M. (1983) Effect of homogenization conditions on the physicochemical properties of emulsion bases. Pharm. Bull. 31, 2786-2792.
81. [81] Washington, C. and Davis, S.S. (1987) Ageing effects in parenteral fat emulsions: the role of fatty acids. Int. J. Pharm. 39, 33-37.
82. [82] Washington, C., Chawla, A., Christy, N. and Davis, S.S. (1989) The electrokinetics properties of phospholipid stabilized fat emulsions. Int. J. Pharm. 54, 191-197.
83. [83] Washington, C. (1990) The electrokinetics properties of phospholipid stabilized fat emulsions. III. Interdroplet potentials and stability ratios in monovalent electrolytes. Int. J. Pharm. 64, 67-73.
84. [84] Washington, C., Athersuch, A. and Kynoch, D.J. (1990) The electrokinetics properties of phospholipid stabilized fat emulsions. IV. The effect of glucose and of pH. Int. J. Pharm. 64, 217-222.
85. [85] Ohki, S. and Arnold, K. (1990) Surface dielectric constant, surface hydrophobicity and membrane fusion. J. Membrane Biol. 114, 195-203.
86. [86] Ohki, S. and Zschorning, O. (1993) Ion-induced fusion of phosphatidic acid vesicles and correlation between surface hydrophobicity and membrane fusion. Chem. Phys. Lipids 65, 193-204.
87. [87] Derjaguin, B.V. and Landau, L.D. (1941) Theory of the stability of strongly lyophobic sols and of the adhesion of strongly changed particles in solutions of electrolytes. Acta Physicochim. 14, 633-662.
88. [88] Verwey, E.J.W. and Overbeek, J.T.G. (1948) Theory of the Stability of Lyophobic Colloids. Elsevier, Amsterdam.
89. [89] Ohki, S., Roy, S., Ohshima, H. and Leonards, K. (1984) Monovalent cation-induced phospholipid vesicle aggregation: effect of ion binding. Biochemistry 23, 6126-6132.
90. [90] Ohki, S. (1984) Effects of divalent cations, temperature, osmotic pressure gradient and vesicle curvature on phosphatidylserine vesicle fusion. J. Membrane Biol. 77, 265-275.
91. [91] Yamaguchi, T., Nishizaki, K., Itai, S., Hayashi, H. and Ohshima, H. (1995) Physicochemical characterization of parenteral lipid emulsion: determination of Hamaker constants and activation energy of coalescence. Pharm. Res. 12, 342-347.
92. [92] Ohshima, H., Healy, T.W. and White, L.R. (1982) Accurate analytic expressions for the surface charge density: surface potential relationship and double-layer potential distribution for a spherical colloidal particle. J. Colloid Interface Sci. 90, 17-26.
93. [93] Derjaguin, B.A. (1934) Untersuchungen über die reibung und adhäsion IV: theorie des anhaftens kleiner teichen. Kolloid Z. 69, 155-164.
94. [94] Lawrence, A.S.C, and Mills, O.S. (1964) Kinetics of the flocculation of emulsions. Discussion of Faraday Soc. 18, 98-104.
95. 2+ in dipalmitoyl phosphatidylcholine/water system. J. Colloid Interface Sci. 86, 57-72.